［1］ IMANI S，BUSCHER H，MARRIOTT D，et al. Too much of a good thing：a retrospective study of β-lactam concentration-toxicity relationships. J Antimicrob Chemother，2017，72（10）：2891-2897.

［2］ BEUMIER M，CASU GS，HITES M，et al. Elevated Beta-lactam concentrations are associated with neurological deterioration in ICU septic patients. Minerva Anestesiologica，2014，81（5）：497-506.

［3］ TRÖGER U，DRUST A，MARTENS-LOBENHOFFER J，et al. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance：benefit of therapeutic drug monitoring. Int J Antimicrob Agents，2012，40（4）：370-372.

［4］ SJÖVALL F，ALOBAID AS，WALLIS SC，et al. Maximally effective dosing regimens of meropenem in patients with septic shock. J Antimicrob Chemother，2018，73（1）：191-198.

［5］ WONG G，BRINKMAN A，BENEFIELD RJ，et al. An international，multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother，2014，69（5）：1416-1423.

［6］ DE WAELE JJ，CARRETTE S，CARLIER M，et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem：a randomised controlled trial. Intensive Care Med，2014，40（3）：380-387.

［7］ FOURNIER A，EGGIMANN P，PAGANI JL，et al. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.Burns，2015，41（5）：956-968.

［8］ WISKIRCHEN DE，HOUSMAN ST，QUINTILIANI R，et al. Comparative pharmacokinetics，pharmacodynamics，and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. Pharmacotherapy，2013，33（33）：266-274.

［9］ WONG G，FARKAS A，SUSSMAN R，et al. Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients.Antimicrob Agents Chemother，2015，59（3）：1411-1417.

［10］ IKAWA K，MORIKAWA N，OHGE H，et al. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother，2010，16（1）：25-32.